WALTHAM, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of Ashish Dugar, Ph.D., MBA, as senior vice president, global head of medical affairs. Dr. Dugar brings over 20 years of broad experience across medical affairs, clinical and commercial development, and real-world evidence (RWE) generation.
“We are thrilled to welcome Ash to the Dyne team and he’ll play an instrumental role in our efforts to develop life-transforming therapies for patients. He has deep experience across clinical, commercial, patient advocacy, RWE, and market access with leading drug development companies and proven success in building a global medical affairs organization in rare muscle disease,” said Joshua Brumm, president and chief executive officer of Dyne. “Ash is representative of the exceptional talent we have been fortunate to attract to Dyne as we execute on our vision of building the world’s leading muscle disease company.”
Prior to joining Dyne, Dr. Dugar served as vice president and global head of medical affairs at Sarepta Therapeutics, Inc., where he built the company’s medical affairs organization. Previously, he led all commercial and market access efforts for Intra-Cellular Therapies, Inc. as vice president and head of commercial development. Dr. Dugar joined Intra-Cellular Therapies following his tenure at Roche, where he was global head of clinical development science and innovation and global head of the external development group, including work in oligonucleotides. Previously, he spent 13 years at Pfizer Inc. in various roles, most recently serving as vice president, global head of clinical development and medical affairs of the biosimilars business unit. Dr. Dugar began his career at the National Institutes of Health. He completed a pharmacoeconomics and outcomes research fellowship at the University of Michigan School of Public Health. Dr. Dugar earned an MBA from The Pennsylvania State University and a Ph.D. in pharmacology from The Pennsylvania State University College of Medicine.
“Dyne is leading a novel approach to solving historical challenges in the development and delivery of modern oligonucleotide therapies for rare muscle diseases, an area I’m incredibly passionate about given the vast unmet patient need. With platform-validating preclinical data and the opportunity to deliver first- and best-in-class therapies at a company with a strong culture focused on innovation and excellence in execution, I am excited to join the team at this pivotal time. Dyne is well positioned for success as we work to advance our three programs into clinical trials,” said Dr. Dugar.
About Dyne Therapeutics
Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approaches. Dyne’s broad portfolio of therapeutic candidates for serious muscle diseases includes programs for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on Twitter, LinkedIn and Facebook.
